Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cardiovascular Diseases
Conditions
Cardiovascular Diseases
Trial Timeline
Nov 28, 2017 → May 1, 2021
NCT ID
NCT03296540About Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets) is a approved stage product being developed by Daiichi Sankyo for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03296540. Target conditions include Cardiovascular Diseases.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03296540 | Approved | Completed |
Competing Products
20 competing products in Cardiovascular Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| Evacetrapib | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Prasugrel (CS-747) + Clopidogrel | Eli Lilly | Phase 2 | 52 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin | Yuhan | Approved | 85 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Lexiscan | Astellas Pharma | Phase 2 | 52 |
| mirabegron + tamsulosin | Astellas Pharma | Phase 1 | 33 |
| TRC150094 | Torrent Pharmaceuticals | Phase 1/2 | 41 |
| Lorcaserin hydrochloride + Placebo | Eisai | Approved | 85 |
| Lepodisiran Sodium + Placebo | Eli Lilly | Phase 3 | 77 |
| Retatrutide + Placebo | Eli Lilly | Phase 3 | 77 |
| Empagliflozin + Placebos | Eli Lilly | Approved | 85 |
| Evacetrapib + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + AZD0780 | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| Midazolam + AZD5718 | AstraZeneca | Phase 1 | 33 |
| 14C]AZD4831 Oral Solution | AstraZeneca | Phase 1 | 33 |